Salarius Pharmaceuticals, Inc. (SLRX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Salarius Pharmaceuticals, Inc. (SLRX)
Go deeper and ask any question about SLRX
Company Performance
Current Price
as of Sep 13, 2024$1.56
P/E Ratio
N/A
Market Cap
$2.25M
Description
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.
Metrics
Overview
- HQHouston, TX
- SectorHealth Technology
- IndustryBiotechnology
- TickerSLRX
- Price$1.56+1.30%
Trading Information
- Market Cap$2.25M
- Float97.48%
- Average Daily Volume (1m)111,126
- Average Daily Volume (3m)2,472,009
- EPS-$12.64
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$1.42M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$1.47M
- EV-$1.84M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account